Skip to content
Emend, Ivemend(fosaprepitant dimeglumine)
Emend, Ivemend (fosaprepitant dimeglumine) is a small molecule pharmaceutical. Fosaprepitant dimeglumine was first approved as Ivemend on 2008-01-11. It has been approved in Europe to treat neoplasms and vomiting. It is known to target substance-P receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Emend (generic drugs available since 2016-06-09)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fosaprepitant dimeglumine
Tradename
Company
Number
Date
Products
EMENDMerck Sharp & DohmeN-022023 RX2010-11-12
1 products, RLD, RS
FOSAPREPITANT DIMEGLUMINETevaN-210064 RX2019-09-05
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aponvieNew Drug Application2023-03-06
fosaprepitantANDA2019-09-05
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
FOSAPREPITANT DIMEGLUMINE, EMEND, MERCK AND CO INC
2025-05-02D-186
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A04: Antiemetics and antinauseants
— A04A: Antiemetics and antinauseants
— A04AD: Other antiemetics in atc
— A04AD12: Aprepitant
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver failureD017093HP_0001399K72.9—1———1
Drug overdoseD062787—1———1
Chemical and drug induced liver injuryD056486—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hereditary corneal dystrophiesD003317H18.51————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PoisoningD011041EFO_0008546T65.91————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFOSAPREPITANT DIMEGLUMINE
INNaprepitant
Description
Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic medication, administered intravenously. It is a prodrug of aprepitant.
Classification
Small molecule
Drug classphosphoro-derivatives; tachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Identifiers
PDB—
CAS-ID172673-20-0
RxCUI1731071
ChEMBL IDCHEMBL1201782
ChEBI ID64311
PubChem CID219090
DrugBankDB06717
UNII ID1NF15YR6UY (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
6869
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
P25103
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Variants
Clinical Variant
No data
Financial
Emend - Merck Sharp & Dohme
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,750 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
69 adverse events reported
View more details